Biocon ocrelizumab patent?

Ocrelizumab (brand name Ocrevus) was developed by Genentech (a Roche company), and its patents are held by Genentech/Roche, not by Biocon.

That said, Biocon is known more for biosimilar development and manufacturing, so depending on what you mean by “Biocon ocrelizumab patent,” the situation is usually one of these:

1) Biocon’s biosimilar patents (if any): Biocon may hold patents related to their biosimilar candidate (process, formulations, methods of use, formulation/manufacturing improvements, etc.).
2) Licensed rights: Biocon/Roche-type partnerships (if applicable) could involve rights, but the core product patent for ocrelizumab is generally tied to Genentech/Roche.
3) Regulatory exclusivity/patent status: Even if a biosimilar has its own patents, it still must navigate the originator’s composition/use/manufacturing patents and regulatory exclusivities.

To give you the exact answer, I need one detail:
- Are you asking about (A) the originator patent holder for ocrelizumab, or (B) whether Biocon has its own patents for a biosimilar of ocrelizumab, or (C) the status/expiry timeline for a specific patent?

If you can tell me the jurisdiction (US/EU/India) and the patent number (if you have it) or the biosimilar name/code Biocon is working on, I can be much more precise.